What Are the Best Cancer Treatment Drugs Available in the US?

A complete guide to FDA-approved chemotherapy, targeted therapy, immunotherapy, and hormonal treatment options for American patients in 2025

Medical Disclaimer: This article is for informational purposes only. All cancer treatment decisions must be made by a licensed oncologist. Never self-medicate or purchase cancer drugs without a proper diagnosis and prescription from a qualified physician.

Cancer is the second leading cause of death in the United States and the leading cause of death among Americans younger than 85. According to the American Cancer Society’s Cancer Facts and Figures 2025, an estimated 2,041,910 new cancer cases will be diagnosed in the US in 2025 and 618,120 Americans will die from the disease, roughly 1,700 deaths every single day.

The picture, however, is not entirely bleak. The overall US cancer death rate has been declining steadily since the early 1990s. According to the AACR Cancer Progress Report 2025, more than 4.5 million cancer deaths have been avoided between 1991 and 2023 because of improvements in early detection, reduced smoking rates, and significantly better treatments. As of January 2025, approximately 18.6 million cancer survivors were living in the United States.

Much of that progress is driven by the drugs covered in this guide. Whether you are a patient, caregiver, or healthcare provider, understanding which cancer treatment drugs are available in the US, what they treat, and how to access them is essential knowledge.

The Most Common Cancers in the United States (2025)

Understanding which cancers are most prevalent shapes which drugs are most widely available and most actively developed. According to NCI cancer statistics for 2025, the most common cancers in the US by new case volume are breast cancer, prostate cancer, lung and bronchus cancer, colorectal cancer, melanoma, bladder cancer, kidney cancer, uterine cancer, leukemia, and pancreatic cancer.

For men, prostate, lung, and colorectal cancers account for 48 percent of all new diagnoses. For women, breast, lung, and colorectal cancers account for 51 percent of all new diagnoses. The drugs discussed in this guide are organized around these most common cancer types.

The Four Main Categories of Cancer Treatment Drugs in the US

FDA-approved cancer treatments fall into four main categories. Understanding these helps patients and families make sense of a treatment plan and ask better questions of their oncology team.

1. Chemotherapy (Cytotoxic Drugs)

Chemotherapy drugs kill fast-dividing cancer cells throughout the body. They remain a cornerstone of cancer treatment across nearly every cancer type, often used in combination with surgery, radiation, and newer targeted or immunotherapy agents. The FDA has approved dozens of chemotherapy drugs for use in the US, and most are now available as generics at significantly reduced cost.

The most widely used and available chemotherapy drugs in the US include:

• Paclitaxel (Taxol) and Docetaxel: Taxane drugs used in breast, lung, ovarian, and prostate cancers. Among the most commonly administered chemotherapy agents in US oncology centers.
• Carboplatin and Cisplatin: Platinum-based agents used across lung, ovarian, bladder, cervical, and head and neck cancers. Frequently combined with immunotherapy in current treatment regimens.
• Cyclophosphamide: An alkylating agent used for breast cancer, lymphoma, and leukemia. A core component of the AC regimen for breast cancer.
• Doxorubicin (Adriamycin): Used in breast cancer, sarcoma, and lymphoma. Part of the widely used AC and CHOP chemotherapy regimens.
• 5-Fluorouracil (5-FU): A foundational drug for colorectal, stomach, and breast cancers. Often combined with leucovorin and oxaliplatin in the FOLFOX regimen for colorectal cancer.
• Gemcitabine: Used in pancreatic, lung, bladder, and ovarian cancers. In 2025 the FDA approved a new intravesical gemcitabine system (Inlexzo) for sustained delivery directly into the bladder for non-muscle invasive bladder cancer.
• Methotrexate: Used in leukemia, lymphoma, and some solid tumors. Available in both oral and injectable form.
• Capecitabine (Xeloda): An oral form of 5-FU used for breast and colorectal cancers. Widely available and allows outpatient self-administration.
• Oxaliplatin: A platinum agent used in the FOLFOX and CAPOX regimens for colorectal cancer.
• Vincristine: Used in leukemia, lymphoma, and some childhood cancers as part of combination regimens.

2. Hormonal (Endocrine) Therapy

Hormonal therapies are among the oldest and most effective cancer treatments for hormone-sensitive cancers. They work by blocking or suppressing the hormones that fuel tumor growth, most commonly estrogen in breast cancer and testosterone in prostate cancer. Many are taken as daily pills, making them practical for long-term outpatient treatment.

Key hormonal drugs available in the US:

• Tamoxifen: The long-standing standard for hormone receptor-positive (ER+/PR+) breast cancer. Patients typically take it for five to ten years after surgery. Available as an inexpensive generic.
• Letrozole (Femara), Anastrozole (Arimidex), and Exemestane (Aromasin): Aromatase inhibitors used in postmenopausal women with hormone receptor-positive breast cancer. Widely available and frequently used as first-line hormonal therapy.
• Imlunestrant: A novel oral selective estrogen receptor degrader (SERD) approved by the FDA in 2025 for postmenopausal women and men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. Highlighted by Targeted Oncology as one of 2025’s pivotal approvals.
• Leuprolide (Lupron, Camcevi), Goserelin (Zoladex): Hormonal injections that suppress testosterone production in prostate cancer. In 2025 the FDA approved a new 3-month formulation of leuprolide mesylate (Camcevi) for advanced prostate cancer.
• Bicalutamide, Enzalutamide (Xtandi), Apalutamide (Erleada), Darolutamide (Nubeqa): Anti-androgen drugs for advanced prostate cancer. Darolutamide (Nubeqa) received FDA approval in June 2025 for metastatic hormone-sensitive prostate cancer, per the ASCO Post.

3. Targeted Therapy

Targeted therapies are designed to attack specific molecular drivers of cancer growth rather than broadly killing all fast-dividing cells. The result is more precise treatment with, in many cases, fewer side effects than traditional chemotherapy. The US leads the world in targeted cancer drug approvals, with the FDA issuing more than 50 oncology approvals in 2025 alone.

The most important targeted drugs available in the US by category:

HER2-Targeting Drugs (Breast, Lung, Gastric Cancer):

• Trastuzumab (Herceptin): The foundational HER2-targeted drug for breast and gastric cancer. Still widely used and available as a biosimilar at lower cost.
• Trastuzumab deruxtecan (Enhertu, T-DXd): An antibody-drug conjugate that received FDA approval in 2025 for HER2-low and HER2-ultralow metastatic breast cancer. See CancerNetwork’s 2025 top approvals list.
• Pertuzumab (Perjeta) and biosimilar Pertuzumab-dpzb (Poherdy): Combined with trastuzumab for HER2-positive breast cancer. The first pertuzumab biosimilar was approved in late 2025, per the AACR Q4 2025 approval review.
• Zongertinib (Hernexeos): An oral HER2 tyrosine kinase inhibitor approved in 2025 for HER2-mutated non-small cell lung cancer. The AACR noted its favorable safety profile and oral administration as significant advantages over existing IV options.

Immunotherapy Checkpoint Inhibitors:

• Pembrolizumab (Keytruda): The most broadly approved PD-1 inhibitor in the world, cleared for over 20 cancer types. In June 2025 the FDA approved Keytruda for resectable locally advanced head and neck squamous cell carcinoma, per Cancer Therapy Advisor.
• Nivolumab (Opdivo) and Ipilimumab (Yervoy): In April 2025, the FDA approved the Opdivo plus Yervoy combination for first-line treatment of metastatic colorectal cancer with MSI-H/dMMR status, and for first-line hepatocellular carcinoma.
• Durvalumab (Imfinzi): Approved in March 2025 for muscle-invasive bladder cancer in combination with gemcitabine and cisplatin as neoadjuvant treatment.
• Atezolizumab (Tecentriq): In October 2025, approved in combination with lurbinectedin (Zepzelca) as first-line maintenance for extensive-stage small cell lung cancer.

CDK4/6 Inhibitors (Breast Cancer):

• Palbociclib (Ibrance), Ribociclib (Kisqali), Abemaciclib (Verzenio): Used in combination with hormonal therapy for hormone receptor-positive, HER2-negative breast cancer. Among the most impactful drug classes in breast oncology over the past decade.

PARP Inhibitors (Ovarian, Breast, Prostate Cancer):

• Olaparib (Lynparza), Niraparib (Zejula), Rucaparib (Rubraca): Used in BRCA-mutated cancers. Rucaparib received FDA traditional approval in December 2025 for BRCA-mutated metastatic castration-resistant prostate cancer, per CURE magazine.

BCR-ABL Inhibitors (Leukemia):

• Imatinib (Gleevec), Dasatinib, Nilotinib, Asciminib: Targeted drugs for chronic myeloid leukemia (CML). Transformed CML from a life-threatening disease into a manageable chronic condition for most patients.

Antibody-Drug Conjugates (ADCs):

• Datopotamab deruxtecan (Datroway): Approved in 2025 for locally advanced or metastatic HR-positive, HER2-negative breast cancer after prior endocrine therapy.
• Telisotuzumab vedotin-tllv (Emrelis): Granted accelerated approval in May 2025 for metastatic non-squamous NSCLC with high c-Met overexpression, described by the AACR Q2 2025 review as the first c-Met-targeted therapy for wild-type c-Met lung cancers.

Best Available FDA-Approved Drugs by Cancer Type

Breast Cancer

Breast cancer is the most common cancer in the US, with 319,750 new cases expected in 2025, according to the NCI Common Cancer Types list. Treatment is guided by the tumor’s subtype.

• Chemotherapy: Paclitaxel, Docetaxel, Cyclophosphamide, Doxorubicin, Capecitabine
• Hormonal therapy (ER+/PR+): Tamoxifen, Letrozole, Anastrozole, Imlunestrant (new 2025)
• Targeted (HER2+): Trastuzumab, Pertuzumab, Enhertu (T-DXd), Datroway
• CDK4/6 inhibitors (ER+/HER2-): Palbociclib, Ribociclib, Abemaciclib
• PARP inhibitors (BRCA-mutated): Olaparib, Niraparib

Prostate Cancer

Prostate cancer is the most common cancer in American men, accounting for 30 percent of all new male cancer diagnoses in 2025.

• Hormonal suppression: Leuprolide (Lupron, Camcevi), Goserelin, Degarelix
• Anti-androgens: Bicalutamide, Enzalutamide (Xtandi), Apalutamide (Erleada), Darolutamide (Nubeqa, newly approved 2025)
• PARP inhibitors: Olaparib (Lynparza), Rucaparib (Rubraca, newly approved Dec 2025) for BRCA-mutated disease
• Targeted radioligand therapy: Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for PSMA-positive metastatic castration-resistant prostate cancer
• Chemotherapy: Docetaxel, Cabazitaxel for castration-resistant disease

Lung Cancer

Lung cancer causes more deaths than colorectal, pancreatic, and breast cancers combined. Treatment is now highly dependent on biomarker testing.

• Immunotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Atezolizumab (Tecentriq), Durvalumab (Imfinzi)
• EGFR-targeted: Osimertinib (Tagrisso), Erlotinib, Gefitinib, Afatinib, Lazertinib (Lazcluze), Amivantamab (Rybrevant)
• HER2-targeted: Zongertinib (Hernexeos, newly approved 2025), Trastuzumab deruxtecan (Enhertu)
• ALK-targeted: Alectinib (Alecensa), Crizotinib (Xalkori), Lorlatinib (Lorbrena)
• Chemotherapy backbone: Carboplatin or Cisplatin with Paclitaxel or Pemetrexed

Colorectal Cancer

• Chemotherapy: 5-FU, Leucovorin, Oxaliplatin (FOLFOX), Irinotecan (FOLFIRI), Capecitabine
• Targeted: Bevacizumab (Avastin) or biosimilars for VEGF inhibition; Cetuximab or Panitumumab for RAS wild-type tumors
• Immunotherapy: Nivolumab plus Ipilimumab (newly approved April 2025 for MSI-H/dMMR metastatic colorectal cancer)
• KRAS G12C inhibitor: Adagrasib (Krazati) and Sotorasib (Lumakras) for KRAS G12C-mutated tumors

Leukemia and Lymphoma

• CML: Imatinib (Gleevec), Dasatinib, Nilotinib, Asciminib (Scemblix)
• CLL/SLL: Ibrutinib (Imbruvica), Acalabrutinib (Calquence), Venetoclax (Venclexta), Pirtobrutinib (Jaypirca, FDA traditional approval December 2025)
• Diffuse large B-cell lymphoma and follicular lymphoma: Rituximab (Rituxan), R-CHOP regimen, Epcoritamab (Epkinly, approved late 2025 for follicular lymphoma)
• Multiple myeloma: Daratumumab (Darzalex), Bortezomib (Velcade), Lenalidomide (Revlimid), Linvoseltamab (Lynozyfic, accelerated approval Q3 2025)
• ALL: Blinatumomab (Blincyto), Inotuzumab ozogamicin, Ponatinib for Ph+ ALL

Ovarian Cancer

• Chemotherapy: Carboplatin plus Paclitaxel as standard first-line regimen
• PARP inhibitors (BRCA-mutated or HRD): Olaparib (Lynparza), Niraparib (Zejula), Rucaparib (Rubraca)
• Bevacizumab: Added to chemotherapy in certain high-risk patients

Pancreatic Cancer

• FOLFIRINOX regimen (5-FU, Leucovorin, Irinotecan, Oxaliplatin) for patients with good performance status
• Gemcitabine plus Nab-paclitaxel (Abraxane) as an alternative first-line regimen
• Olaparib (Lynparza) for maintenance therapy in BRCA-mutated metastatic pancreatic cancer

Notable New Cancer Drug Approvals in the US in 2025

The FDA issued more than 50 oncology approvals in 2025, reinforcing the US position as the world leader in cancer drug development. Here are the standout approvals:

• Imlunestrant: New oral SERD for ESR1-mutated ER+/HER2- advanced breast cancer.
• Zongertinib (Hernexeos): First oral HER2 TKI approved for HER2-mutated lung cancer with broad mutation coverage.
• Trastuzumab deruxtecan (Enhertu): Expanded approval for HER2-low and HER2-ultralow metastatic breast cancer.
• Nivolumab plus Ipilimumab: Approved for first-line MSI-H colorectal cancer and first-line hepatocellular carcinoma.
• Darolutamide (Nubeqa): Approved June 2025 for metastatic hormone-sensitive prostate cancer.
• Rucaparib (Rubraca): Traditional approval December 2025 for BRCA-mutated castration-resistant prostate cancer.
• Datopotamab deruxtecan (Datroway): New TROP2-directed ADC approved for HR+/HER2- breast cancer.
• Pirtobrutinib (Jaypirca): Traditional approval December 2025 for relapsed CLL/SLL after prior BTK inhibitor therapy.
• Epcoritamab (Epkinly): Approved Q4 2025 for relapsed/refractory follicular lymphoma in combination with lenalidomide and rituximab.
• Tarlatamab (Imdelltra): Traditional approval for extensive-stage small cell lung cancer following platinum-based chemotherapy.

How to Access Cancer Drugs in the United States

Most cancer drugs in the US are dispensed through hospital-affiliated specialty pharmacies, oncology infusion centers, or NABP-verified online pharmacies. Here is how patients typically access them:

• Cancer centers and hospital pharmacies: NCI-designated cancer centers provide access to the full range of FDA-approved drugs, including newly approved agents and clinical trial medications. Find one at cancer.gov.
• Retail and specialty pharmacies: Oral cancer drugs including hormonal agents, CDK4/6 inhibitors, and oral targeted therapies are dispensed through major pharmacy chains and specialty pharmacies. Always verify the pharmacy is licensed using the NABP Safe Site Search Tool.
• Patient assistance programs: Most major drug manufacturers operate patient assistance programs for uninsured or underinsured patients. The NeedyMeds database and RxAssist are useful starting points.
• Medicare and Medicaid: Medicare Part B covers infused cancer drugs administered in a clinical setting. Medicare Part D covers oral cancer medications. Medicaid coverage varies by state.
• Clinical trials: Many cutting-edge cancer drugs are available at no cost through clinical trials before full FDA approval. Search at clinicaltrials.gov.

Counterfeit Cancer Drugs: A Real Danger in the United States

Counterfeit cancer drugs are not just a developing-world problem. The FDA regularly intercepts fraudulent cancer medications at US borders and has warned consumers about fake versions of high-cost drugs such as Keytruda, Avastin, and Herceptin circulating through unverified online channels.

The risk is particularly acute with online purchasing. According to the National Association of Boards of Pharmacy (NABP), nearly 95 percent of online pharmacies operating in the US do not comply with US law or safety standards. A fake cancer drug does not simply fail to work. It may contain the wrong active ingredient, a dangerous dose, or no active ingredient at all, putting an already vulnerable patient at serious additional risk.

To protect yourself:

• Buy cancer drugs only through licensed oncology centers, hospital pharmacies, or NABP-verified pharmacies
• Verify any online pharmacy at safe.pharmacy before purchasing
• Check the NDC number on the FDA’s National Drug Code Directory to confirm a drug is legitimate
• If a drug looks different from previous supplies (different color, texture, packaging, or smell), do not take it
• Report suspected counterfeit cancer drugs to FDA MedWatch at fda.gov/safety/medwatch

Find Verified Cancer Drugs Through Pharmachain AI

Even in the US, with the most developed pharmaceutical infrastructure in the world, patients face real challenges finding cancer drugs. Supply shortages affect commonly used chemotherapy agents. Specialty drugs may not be stocked at every pharmacy. Patients managing complex regimens with multiple medications need to coordinate across different dispensing channels. And for anyone researching treatment abroad or supporting a family member in another country, the challenge is even greater.

Pharmachain AI is a verified pharmacy search and drug access platform built to remove these barriers. The platform searches only licensed, regulated pharmacies in real time to confirm stock, compare prices, and connect patients with verified sources for their medications.

For patients managing cancer treatment, Pharmachain AI offers:

• Verified sources only: Every pharmacy in the network is licensed and regulated. No informal markets. No unverified online sellers.
• Real-time stock and price comparison: Know before you travel which pharmacy has your specific cancer drug available and at what cost.
• Up to 10 percent savings: Pharmachain AI negotiates bulk pricing with partner pharmacies so patients access medicines at reduced rates.
• Counterfeit protection: Because the platform only connects patients to verified sources, the risk of receiving a fake or substandard drug is eliminated.
• Earn rewards: New users receive 500 $PHAI tokens. Additional tokens are earned with every verified interaction on the platform.

When you are navigating cancer treatment, every decision carries weight. Knowing your drugs are real, available, and affordable should not be the hardest part.

A cancer diagnosis is not the end of the road.

Effective, FDA-approved treatments exist. Research is accelerating. Know your options, work with your oncologist, verify your medicines, and use trusted platforms to access them.

Frequently Asked Questions About Cancer Drugs in the US